Investment Analysts’ Weekly Ratings Changes for WAVE Life Sciences (WVE)

WAVE Life Sciences (NASDAQ: WVE) recently received a number of ratings updates from brokerages and research firms:

• 2/12/2026 – WAVE Life Sciences had its price target lowered by analysts at Wells Fargo & Company from $29.00 to $27.00. They now have an “overweight” rating on the stock.
• 2/7/2026 – WAVE Life Sciences was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 2/5/2026 – WAVE Life Sciences is now covered by analysts at Bank of America Corporation. They set a “buy” rating and a $38.00 price target on the stock.
• 2/5/2026 – WAVE Life Sciences had its price target raised by analysts at Cantor Fitzgerald from $34.00 to $41.00. They now have an “overweight” rating on the stock.
• 2/3/2026 – WAVE Life Sciences had its price target raised by analysts at Canaccord Genuity Group Inc. from $40.00 to $43.00. They now have a “buy” rating on the stock.
• 1/21/2026 – WAVE Life Sciences had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 1/11/2026 – WAVE Life Sciences was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 1/3/2026 – WAVE Life Sciences was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.

Insiders Place Their Bets

In other WAVE Life Sciences news, insider Chris Francis sold 1,883 shares of the company’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $13.45, for a total value of $25,326.35. Following the sale, the insider directly owned 61,867 shares in the company, valued at $832,111.15. This represents a 2.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, major shareholder Plc Gsk acquired 1,470,000 shares of the business’s stock in a transaction on Thursday, December 11th. The shares were bought at an average cost of $19.00 per share, with a total value of $27,930,000.00. Following the completion of the acquisition, the insider owned 18,245,691 shares of the company’s stock, valued at approximately $346,668,129. This trade represents a 8.76% increase in their position. The SEC filing for this purchase provides additional information. Insiders have sold 915,181 shares of company stock worth $13,612,581 over the last quarter. Corporate insiders own 23.98% of the company’s stock.

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.